Home>Biopharmaceutical Manufacturing>BioReliance® Product Characterization Services

BioReliance® Product Characterization Services


Ask us a question
Cell Line Development Interlot & Biosimilar Comparability Lot Release & Stability Process & Product Impurities


Assay Packages
Cell Line Development

We know how difficult it can be to characterize your biotherapy through the development process due to the required advanced technologies and specialized expertise. Our comprehensive program combines physicochemical and structural information with the activity profile captured from binding, affinity, and potency bioassays to better understand the function of your drug – its critical quality attributes. All testing is compliant with ICH guidelines, FDA, and EMA regulations. Whether you are testing cell pools or isolated clones, we have an assay to suit the level of characterization you require depending on your stage of development:

  • Early material from stable pools or stable cell lines
  • Clone selection
  • Final clone testing
  • Research or master cell bank
Ideal during:
Discovery
Pre-Clinical
Phase I
Phase II
Phase III
Manufacturing

Assay families that satisfy testing needs include:


  • Titer

    Productivity of the cell line to deliver sufficient quantities of your mAb influences its commercial potential. Used as a baseline measurement, titer is measured using Protein-A affinity chromatography (HPLC). Early in the development of a mAb, a large number of harvest cell culture (HCC) samples must be screened for IgG titer. Affinity chromatography employing a Protein A ligand is often used to determine the mAb concentration as well as to purify it for downstream aggregate and charge variant analysis.

  • Doubling rate

    The growth, or doubling rate of the cell line used to produce your mAb is often used as a second decision point by commercial manufacturers like you. The doubling rate reflects the growth potential of the cell line and it influences the amount of mAb product produced as is reflected also by titer.

  • Binding affinity to target (surface plasmon resonance)

    Understanding the binding affinity of your mAb with its intended target is an early indicator of generic binding function. Surface plasmon resonance (SPR) is the gold standard in rapid and high throughput binding analysis which gives detailed kinetic information on the nature as well as strength of binding.

  • N-glycan analysis

    Highly variable glycosylation may impact mAb purity and produce variable function. Monoclonal antibodies carry N-glycans on their backbone that can be released using LC-MS to assess glycosylation patterns. Characterization of the N-glycans from a monoclonal antibody is necessary as part of a work package providing full structural details of the molecule under investigation. Understanding these N-glycan pathways is important because N-glycans affect many properties of glycoproteins including their conformation, solubility, antigenicity, and recognition by glycan-binding proteins.

  • Intact mass

    Determination of the intact molecular mass is a necessary step in characterization of biologics, from clone selection to verification of the final product. Intact molecular mass analysis is commonly used to demonstrate the diversity of the protein/peptide products and verify the identity of the biologics. With optimization, it can also determine the intact molecular weight of all protein products, including bispecific monoclonal antibodies.

  • Potency

    Potency assays are essential in verifying product quality: they prove the drug has achieved its desired effect and strength. Potency assays are needed from early development through commercial release because once a drug is ready for market, a different measurement of potency could be reported. This makes it necessary to have the correct potency assay developed as early as possible to ensure safety and avoid delays in your development plan.

  • Binding via surface plasmon resonance (SPR) scan or ELISA

    The extensive variability of a molecule's physicochemical and structural properties creates extensive diversity in the Fc region of the antibody, for example through differences in glycosylation profile in the Fc region. Structural differences can influence the binding activity with Fc receptors expressed on immune cells which in turn influences the antibody’s effector function and can therefore have a great impact on potency if effector mechanisms are important for mechanism of action. The Fc region plays a critical role in the function of therapeutic antibodies as they can bind to a variety of receptors and other protein components within the immune system.



Hear from Our Experts

Get insight into topics that directly impact your success to clinic. Learn more from our white papers, videos, webinars, and posters.

Knowledge Center

Contact Us

Contact our product characterization experts to discuss your specialized needs and take the next step to securing the future of your biotherapy.

Ask Us a Question Connect with Us on LinkedIn